Professor of Pediatrics, University of Pennsylvania School of Medicine
Director, Center for Childhood Cancer Research
- Department: Pediatrics
- Division: Oncology
- Primary Address:
The Children's Hospital of Philadelphia
Division of Oncology
Colket Translational Research Building
3501 Civic Center Boulevard #3060
Philadelphia, PA 19104
- 215 590 5244
Dr. Maris's research focuses on translational genomics and genetics of neuroblastoma.
- Professor of Pediatrics, University of Pennsylvania School of Medicine (2010 – present)
- Associate Professor of Pediatrics, University of Pennsylvania School of Medicine (2004 – 2010)
- Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine (1996 – 2004)
- M.D., Medicine, University of Pennsylvania (1989)
- B.S., Biology, Wheeling College (1983)
I'm chief of the Division of Oncology at The Children's Hospital of Philadelphia and director of the Center for Childhood Cancer Research. In addition, I direct the Pediatric Oncology Program in the Abramson Cancer Center at the University of Pennsylvania.
At Children's Hospital, I have the honor of leading a team of world-class clinicians and scientists dedicated to rapidly translating research about childhood cancers from the laboratory to the patient. We are one of the nation’s leaders in early phase clinical research that intently focuses on improving pediatric cancer cure rates and minimizing long-term side effects. We design studies to help benefit children who have refractory or relapsed diseases for which treatment options may be limited. As we make new discoveries, our goal is to bring them quickly to young patients.
My own specialty is neuroblastoma, an often intractable cancer that starts in young nerve cells and can be extremely aggressive. I've been interested in this disease since before medical school, when I had the opportunity to work with noted scientists Drs. Audrey Evans and Britton Chance. Under the tutelage of Dr. Garrett Brodeur I focused on the genetic basis of the disease during my training, convinced that seminal changes in patient care would stem from a full understanding of what genes are altered during the formation of this cancer.
To learn more and make a difference as quickly as possible, I developed a laboratory and translational research program at Children's Hospital to help us focus on the genetic abnormalities in hereditary and sporadic neuroblastoma. We strive to exponentially increase our understanding of this cancer and its underlying biology in order to impact clinical practice immediately- an effort we approach with urgency and a large measure of recent success. In the past few years, our team at Children's Hospital has been able to identify the main genes associated with this cancer. As a result, we moved some of these discoveries toward new therapies, a number of which are now in clinical trials. Our goal is to personalize the approach to neuroblastoma, and other pediatric cancers, by selecting treatments based on a full understanding of each individual patient’s cancer genetics.
Our neuroblastoma team has made enormous progress as we translate our basic and clinical research into improved therapies. Patients, their families and referring physicians may be confident that our outstanding clinicians and researchers provide the most comprehensive and cutting edge care possible for children with this difficult cancer.
- Kolb E Anders, Gorlick Richard, Reynolds C Patrick, Kang Min H, Carol Hernan, Lock Richard, Keir Stephen T, Maris John M, Billups Catherine A, Desjardins Christopher, Kurmasheva Raushan T, Houghton Peter J, Smith Malcolm A. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood & Cancer. Vol 60(8) . 2013 Aug:1325-32.
- Wang Larry L, Suganuma Rie, Ikegaki Naohiko, Tang Xao, Naranjo Arlene, McGrady Patrick, London Wendy B, Hogarty Michael D, Gastier-Foster Julie M, Look A Thomas, Park Julie R, Maris John M, Cohn Susan L, Seeger Robert C, Shimada Hiroyuki. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. Cancer. 2013 Jul.
- Kreissman Susan G, Seeger Robert C, Matthay Katherine K, London Wendy B, Sposto Richard, Grupp Stephan A, Haas-Kogan Daphne A, Laquaglia Michael P, Yu Alice L, Diller Lisa, Buxton Allen, Park Julie R, Cohn Susan L, Maris John M, Reynolds C Patrick, Villablanca Judith G. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. The Lancet Oncology. 2013 Jul.
- Maurer Barry J, Kang Min H, Villablanca Judith G, Janeba Jitka, Groshen Susan, Matthay Katherine K, Sondel Paul M, Maris John M, Jackson Hollie A, Goodarzian Fariba, Shimada Hiroyuki, Czarnecki Scarlett, Hasenauer Beth, Reynolds C Patrick, Marachelian Araz. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium. Pediatric Blood & Cancer. 2013 Jun.
- Wood Andrew C, Maris John M, Gorlick Richard, Kolb E Anders, Keir Stephen T, Reynolds C Patrick, Kang Min H, Wu Jianrong, Kurmasheva Raushan T, Whiteman Kathleen, Houghton Peter J, Smith Malcolm A. Initial testing (stage 1) of the antibody-maytansinoid conjugate, IMGN901 (lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatric Blood & Cancer. 2013 Jun.
- Mosse Yael P, Lim Megan S, Voss Stephan D, Wilner Keith, Ruffner Katherine, Laliberte Julie, Rolland Delphine, Balis Frank M, Maris John M, Weigel Brenda J, Ingle Ashish M, Ahern Charlotte, Adamson Peter C, Blaney Susan M. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. The Lancet Oncology. Vol 14(6) . 2013 May:472-80.
- Yanik Gregory A, Parisi Marguerite T, Shulkin Barry L, Naranjo Arlene, Kreissman Susan G, London Wendy B, Villablanca Judith G, Maris John M, Park Julie R, Cohn Susan L, McGrady Patrick, Matthay Katherine K. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Journal of Nuclear Medicine. Vol 54(4) . 2013 Apr:541-8.
- Suganuma Rie, Wang Larry L, Sano Hideki, Naranjo Arlene, London Wendy B, Seeger Robert C, Hogarty Michael D, Gastier-Foster Julie M, Look A Thomas, Park Julie R, Maris John M, Cohn Susan L, Amann Gabriele, Beiske Klaus, Cullinane Catherine J, d'Amore Emanuele S G, Gambini Claudio, Jarzembowski Jason A, Joshi Vijay V, Navarro Samuel, Peuchmaur Michel, Shimada Hiroyuki. Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatric Blood & Cancer. Vol 60(3) . 2013 Mar:363-70.
- Mayes Patrick A, Degenhardt Yan Y, Wood Andrew, Toporovskya Yana, Diskin Sharon J, Haglund Elizabeth, Moy Christopher, Wooster Richard, Maris John M. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. International Journal of Cancer. Vol 132(3) . 2013 Feb:E149-57.
- Seif A E, Naranjo A, Baker D L, Bunin N J, Kletzel M, Kretschmar C S, Maris J M, McGrady P W, von Allmen D, Cohn S L, London W B, Park J R, Diller L R, Grupp S A. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplantation. 2013 Jan.